The biopharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~8%, till 2030
Roots Analysis has done a detailedstudy on Biopharma Contract ManufacturingMarket (3rd Edition), 2019-2030, covering key aspects of the industry’sevolution and identifying potential future growth opportunities.
To order this 750+page report, which features 200+ figures and 250+ tables, please visit this link
Key Market Insights
§ Over 235 companiesworldwide claim to offer contract manufacturing services for various types ofbiopharmaceutical drug / therapy products.
§ The market landscapeis highly fragmented featuring the presence of both established players and newentrants; majority of biopharmaceutical CMOs are based in the developed geographies.
§ Case study: CMOsfocusing on niche biologic markets, primarily novel product candidates forwhich in-house biomanufacturing expertise is low, are likely to experiencesignificant growth in the coming years.
§ The installed globalcontract manufacturing capacity, spread across various geographies, iscurrently estimated to be over 4.5 million liters.
§ The demand for contract manufacturing services is expected to riseacross different therapeutic areas; closer inspection of available capacity andexpected utilization trend are required to optimize supply parameters.
§ With over 450 dealsinked in the past six years, there has been a surge in the partnershipactivity; majority of the collaborations have been signed for the developmentand manufacturing of cell therapies and antibodies.
§ In order to cater the increasing demand for biologics, stake holders areactively expanding their existing capabilities; this is evident from thevarious acquisitions that have recently been reported.
§ We expect the developersto continue to outsource their manufacturing operations in the short tomid-term, resulting in an annualized growth rate of more than 8%.
§ In the long term, theprojected opportunity is anticipated to be well distributed across varioustypes of expression systems used for biomanufacturing, scale of operation andsize of contract service providers
For more information, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Contextand Background
3.2. AnOverview of Biopharmaceuticals
3.3. BiopharmaceuticalManufacturing
3.3.1. Typesof Expression Systems
3.3.1.1. BacterialExpression Systems
3.3.1.2. YeastExpression Systems
3.3.1.3. FungalExpression Systems
3.3.1.4. InsectExpression Systems
3.3.1.5. Plant Expression Systems
3.3.1.6. Mammalian Expression Systems
3.3.2. ManufacturingSteps
3.3.2.1. UpstreamProcessing
3.3.2.2. Downstream Processing
3.4. AnOverview of Contract Manufacturing
3.5. Needfor Outsourcing in the Biopharmaceutical Industry
3.6. CommonlyOutsourced Operations in the Biopharmaceutical Industry
3.7. BasicGuidelines for Selecting a CMO Partner
3.8. Advantagesof Outsourcing Manufacturing Services
3.9. Risksand Challenges Associated with Biopharmaceutical Contract Manufacturing
3.10. ConcludingRemarks
4. COMPETITIVELANDSCAPE
4.1. ChapterOverview
4.2. BiopharmaceuticalsContract Manufacturers: Overall Market Landscape
4.2.1. Analysisby Size of Employee Base
4.2.2. Analysisby Location of Headquarters
4.2.3. Analysisby Year of Establishment
4.2.4. Analysisby Location of Manufacturing Facilities
4.2.5. Analysisby Type of Biologics Manufactured
4.2.6. Analysisby Scale of Operation
4.2.7. Analysisby Expression Systems
4.2.8. Analysisby Type of Bioreactor and Modes of Operation
4.2.9. Analysisby Biomanufacturing Capacity
4.2.10. Analysis by Packaging Form
4.3. ConcludingRemarks
5. BIOPHARMACEUTICALCONTRACT MANUFACTURING IN NORTH AMERICA
5.1. ChapterOverview
5.2. BiopharmaceuticalOutsourcing in the US: Regulatory Scenario
5.2.1. Impactof Current Political Situation
5.3. LeadingBiopharma CMOs in North America
5.3.1. AMRI(OsoBio)
5.3.1.1. CompanyOverview
5.3.1.2. ServicesPortfolio
5.3.1.3. FinancialInformation
5.3.1.4. ManufacturingFacilities
5.3.1.5. Partnerships
5.3.1.6. RecentDevelopments
5.3.1.7. FutureOutlook
5.3.2. BaxterBioPharma Solutions
5.3.2.1. CompanyOverview
5.3.2.2. ServicesPortfolio
5.3.2.3. FinancialInformation
5.3.2.4. ManufacturingFacilities
5.3.2.5. Partnerships
5.3.2.6. RecentDevelopments
5.3.2.7. FutureOutlook
5.3.3. CatalentBiologics (Catalent Pharma Solutions)
5.3.3.1. CompanyOverview
5.3.3.2. ServicesPortfolio
5.3.3.3. FinancialInformation
5.3.3.4. ManufacturingFacilities
5.3.3.5. Partnerships
5.3.3.6. RecentDevelopments
5.3.3.7. FutureOutlook
5.3.4. CytovanceBiologics
5.3.4.1. CompanyOverview
5.3.4.2. ServicesPortfolio
5.3.4.3. Partnerships
5.3.4.4. RecentDevelopments
5.3.4.5. FutureOutlook
5.3.5. Patheon
5.3.5.1. Company Overview
5.3.5.2. ServicesPortfolio
5.3.5.3. FinancialInformation
5.3.5.4. ManufacturingFacilities
5.3.5.5. Partnerships
5.3.5.6. RecentDevelopments
5.3.5.7. FutureOutlook
5.3.6. PiramalPharma Solutions
5.3.6.1. CompanyOverview
5.3.6.2. ServicesPortfolio
5.3.6.3. FinancialInformation
5.3.6.4. Facilities
5.3.6.5. Partnerships
5.3.6.6. RecentDevelopments
5.3.6.7. FutureOutlook
6. BIOPHARMACEUTICAL CONTRACT MANUFACTURINGIN EUROPE
6.1. ChapterOverview
6.2. BiopharmaceuticalOutsourcing in Europe: Regulatory Scenario
6.3. LeadingBiopharmaceutical CMOs in Europe
6.3.1. 3PBiopharmaceuticals
6.3.1.1. CompanyOverview
6.3.1.2. ServicesPortfolio
6.3.1.3. ManufacturingFacilities
6.3.1.4. Partnerships
6.3.1.5. RecentDevelopments
6.3.1.6. FutureOutlook
6.3.2. BoehringerIngelheim BioXcellence™
6.3.2.1. CompanyOverview
6.3.2.2. ServicesPortfolio
6.3.2.3. FinancialInformation
6.3.2.4. ManufacturingFacilities
6.3.2.5. Partnerships
6.3.2.6. RecentDevelopments
6.3.2.7. FutureOutlook
6.3.3. Celonic
6.3.3.1. CompanyOverview
6.3.3.2. ServicesPortfolio
6.3.3.3. ManufacturingFacilities
6.3.3.4. Partnerships
6.3.3.5. RecentDevelopments
6.3.3.6. FutureOutlook
6.3.4. FUJIFILMDiosynth Biotechnologies
6.3.4.1. CompanyOverview
6.3.4.2. ServicesPortfolio
6.3.4.3. FinancialInformation
6.3.4.4. ManufacturingCapabilities
6.3.4.5. Partnerships
6.3.4.6. RecentDevelopments
6.3.4.7. FutureOutlook
6.3.5. LFBGroup
6.3.5.1. CompanyOverview
6.3.5.2. ServicesPortfolio
6.3.5.3. FinancialInformation
6.3.5.4. ManufacturingFacilities
6.3.5.5. Partnerships
6.3.5.6. RecentDevelopments
6.3.5.7. FutureOutlook
6.3.6. Lonza
6.3.6.1. CompanyOverview
6.3.6.2. ServicesPortfolio
6.3.6.3. FinancialInformation
6.3.6.4. ManufacturingFacilities
6.3.6.5. Partnerships
6.3.6.6. RecentDevelopments
6.3.6.7. FutureOutlook
6.3.7. MenariniBiotech
6.3.7.1. CompanyOverview
6.3.7.2. ServicesPortfolio
6.3.7.3. Partnerships
6.3.7.4. FutureOutlook
6.3.8. Novasep
6.3.8.1. CompanyOverview
6.3.8.2. ServicesPortfolio
6.3.8.3. FinancialInformation
6.3.8.4. Partnerships
6.3.8.5. RecentDevelopments
6.3.8.6. FutureOutlook
6.3.9. RentschlerBioPharma
6.3.9.1. CompanyOverview
6.3.9.2. ServicesPortfolio
6.3.9.3. ManufacturingFacilities
6.3.9.4. Partnerships
6.3.9.5. RecentDevelopments
6.3.9.6. FutureOutlook
7. BIOPHARMACEUTICAL CONTRACT MANUFACTURINGIN ASIA PACIFIC AND THE REST OF THE WORLD
7.1. ChapterOverview
7.2. BiopharmaceuticalContract Manufacturing in China
7.2.1. BiopharmaceuticalOutsourcing in China: Regulatory Scenario
7.2.2. ChallengesFaced while Outsourcing to China
7.3. BiopharmaceuticalCMOs in China
7.3.1. AutekBio
7.3.1.1. CompanyOverview
7.3.1.2. ServicesPortfolio
7.3.1.3. ManufacturingFacilities
7.3.1.4. FutureOutlook
7.3.2. WuXiAppTec (WuXi Biologics)
7.3.2.1. CompanyOverview
7.3.2.2. ServicesPortfolio
7.3.2.3. FinancialInformation
7.3.2.4. ManufacturingFacilities
7.3.2.5. Partnerships
7.3.2.6. RecentDevelopments
7.3.2.7. FutureOutlook
7.4. BiopharmaceuticalContract Manufacturing in India
7.4.1. BiopharmaceuticalOutsourcing in India: Regulatory Scenario
7.4.2. ChallengesFaced while Outsourcing to India
7.5. BiopharmaceuticalCMOs in India
7.5.1. IntasPharmaceuticals
7.5.1.1. CompanyOverview
7.5.1.2. ServicesPortfolio
7.5.1.3. FinancialInformation
7.5.1.4. ManufacturingFacilities
7.5.1.5. FutureOutlook
7.5.2. KemwellBiopharma
7.5.2.1. CompanyOverview
7.5.2.2. ServicesPortfolio
7.5.2.3. ManufacturingFacilities
7.5.2.4. Partnerships
7.5.2.5. RecentDevelopments
7.5.2.6. FutureOutlook
7.5.3. ShasunPharmaceuticals
7.5.3.1. CompanyOverview
7.5.3.2. ServicesPortfolio
7.5.3.3. FinancialInformation
7.5.3.4. FutureOutlook
7.5.5. Syngene
7.5.5.1. CompanyOverview
7.5.5.2. ServicesPortfolio
7.5.5.3. FinancialInformation
7.5.5.4. ManufacturingFacilities
7.5.5.5. Partnerships
7.5.5.6. RecentDevelopments
7.5.5.7. FutureOutlook
7.6. BiopharmaceuticalContract Manufacturing in Japan
7.6.1. BiopharmaceuticalOutsourcing in Japan: Regulatory Scenario
7.6. BiopharmaceuticalCMOs in Japan
7.6.1. AsahiGlass
7.6.1.1. CompanyOverview
7.6.1.2. ServicesPortfolio
7.6.1.3. FinancialInformation
7.6.1.4. ManufacturingFacilities
7.6.1.5. Partnerships
7.7.1.6. RecentDevelopments
7.7.1.7. FutureOutlook
7.7. BiopharmaceuticalContract Manufacturing in South Korea
7.7.1. BiopharmaceuticalOutsourcing in South Korea: Regulatory Scenario
7.7. BiopharmaceuticalCMOs in South Korea
7.7.1. DMBio
7.7.1.1. CompanyOverview
7.7.1.2. ServicesPortfolio
7.7.1.3. ManufacturingFacilities
7.7.1.4. FutureOutlook
7.7.2. SamsungBioLogics
7.7.2.1. CompanyOverview
7.7.2.2. ServicesPortfolio
7.7.2.3. FinancialInformation
7.7.2.4. ManufacturingFacilities
7.7.2.5. Partnerships
7.7.2.6. RecentDevelopments
7.7.2.7. FutureOutlook
7.8. BiopharmaceuticalContract Manufacturing in Australia
7.8.1. BiopharmaceuticalOutsourcing in Australia: Regulatory Scenario
7.8. BiopharmaceuticalCMOs in Australia
7.8.2. CellTherapies
7.8.2.1. CompanyOverview
7.8.2.2. ServicesPortfolio
7.8.2.3. ManufacturingFacilities
7.8.2.4. Partnerships
7.8.2.5. RecentDevelopments
7.8.2.6. FutureOutlook
7.8.3. LuinaBio
7.8.3.1. CompanyOverview
7.8.3.2. ServicesPortfolio
7.8.3.3. ManufacturingFacilities
7.8.3.4. Partnerships
7.8.3.5. FutureOutlook
8. NICHEBIOPHARMACEUTICAL SECTORS
8.1. ChapterOverview
8.2. AntibodyDrug Conjugates
8.2.1. Introduction
8.2.1.1. ManufacturingProcess
8.2.1.2. KeyTechnologies and Technology Providers
8.2.2. PipelineAnalysis
8.2.2.1. ADCPipeline: Marketed and Clinical Molecules
8.2.2.2. ADCPipeline: Preclinical and Discovery Stage Molecules
8.2.2.3. ADCManufacturing: Key Challenges
8.3. BispecificAntibodies
8.3.1. Introduction
8.3.1.1. TheBispecific Advantage
8.3.2. PipelineAnalysis
8.3.3. BispecificAntibody Technology Providers
8.3.4. ContractManufacturing Scenario
8.4. CellTherapies
8.4.1. Introduction
8.4.2. CurrentMarket Landscape
8.4.3. CellTherapy Manufacturing
8.4.4. CellTherapy Manufacturing Models
8.4.4.1. CentralizedManufacturing Model
8.4.4.2. DecentralizedManufacturing Model
8.4.5. CellTherapy Manufacturing: Key Challenges and Growth Drivers
8.4.6. ImportantFactors for Cell Therapy Manufacturing
8.4.6.1. Cell Characterization
8.4.6.2. Cost of Goods
8.4.7. ContractManufacturing Scenario
8.4.7.1. Analysisby Type of Cells Manufactured
8.4.7.2. Analysisby Scale of Operation
8.5. GeneTherapy
8.5.1. Introduction
8.5.2. GeneTherapy: Pipeline Analysis
8.5.2.1. Analysisby Phase of Development
8.5.2.2. Analysisby Type of Vector
8.5.2.3. Analysisby Therapeutic Area
8.5.3. ContractManufacturing Market Landscape
8.5.3.1. Analysisby Location
8.5.3.2. Analysisby Type of Viral Vector
8.5.3.3. Analysisby Scale of Production
8.6. PlasmidDNA
8.6.1. Introduction
8.6.2. ContractManufacturing Market Landscape
8.6.3. Analysisby Location of Manufacturing Facility
8.6.4. Analysisby Scale of Production
9. CASE STUDY:OUTSOURCING OF BIOSIMILARS
9.1. ChapterOverview
9.2. Biosimilars:An Introduction
9.3. Biosimilars:Development Stages
9.4. RegulatoryRequirements for Licensing of Biosimilars
9.5. Needfor Outsourcing Biosimilar Development and Manufacturing
9.6. Impactof Biosimilars on the Global Contract Manufacturing Market
9.6.1. Region-wiseDistribution of Biosimilar Development / Manufacturing Activity
9.7. Listof Biosimilars Contract Manufacturing Service Provider
9.8. ChallengesAssociated with Biosimilar Outsourcing
10. CASE STUDY:COMPARISON OF SMALL AND LARGE MOLECULE DRUGS / THERAPIES
10.1. ChapterOverview
10.2. SmallMolecule and Large Molecule Drugs / Therapies
10.2.1. Comparisonof General Characteristics
10.2.2. Comparisonof Key Specifications
10.2.3. Comparisonof Manufacturing Processes
10.2.4. Comparisonof Key Manufacturing Challenges
11. CASE STUDYON IN-HOUSE MANUFACTURING
11.1. ChapterOverview
11.2. In-HouseManufacturing
11.2.1. BenefitsAssociated with In-House Manufacturing
11.2.2. RisksAssociated with In-House Manufacturing
11.3. Outsourcingin the Biomanufacturing Industry
11.3.1. Typesof Outsourcing Partners
11.4. ManufacturingApproaches Used for Approved Biologics (2016-2018)
11.4.1. ApprovedBiologics: Distribution by Size of Type of Manufacturing Approach
11.4.2. ApprovedBiologics: Distribution by Size of Developer and Type of Biologic
11.5. Choosingthe Right Strategy: In-House Manufacturing versus Outsourcing
12. COLLABORATIONS
12.1. ChapterOverview
12.2. PartnershipModels
12.3. BiopharmaceuticalContract Manufacturing: List of Partnerships and Collaborations
12.3.1. Analysisby Year of Partnerships
12.3.2. Analysisby Type of Partnerships
12.3.2.1. Year-Wise Trend ofProduct-based Agreements
12.3.2.2. Year-Wise Trend ofProcess-based Agreements
12.3.2.3. Year-Wise Trend of LicensingAgreements
12.3.2.4. Year-Wise Trend of Co-serviceAgreements / Ventures
12.3.2.5. Year-Wise Trend of R&DAgreements
12.3.2.6. Year-Wise Trend ofOut-sourcing Services Agreements
12.3.3. Analysisby Focus Area
12.3.4. Analysisby Type of Biologics
12.3.4.1. Analysis by Type of Biologicand Type of Partnership Model
12.3.4.2. Analysis of CellTherapy-related Deals by Year and Type of Partnership Model
12.3.4.3. Analysis of MonoclonalAntibody-related Deals by Year and Type of Partnership Model
12.3.4.4. Analysis of Vaccine-relatedDeals by Year and Type of Partnership Model
12.3.4.5. Analysis of Protein-relatedDeals by Year and Type of Partnership Model
12.3.4.6. Analysis of Antibody DrugDeals by Year and Type of Partnership Model
12.3.4.7. Analysis of Vector-relatedDeals by Year and Type of Partnership Model
12.3.4.8. Analysis of GeneTherapy-related Deals by Year and Type of Partnership Model
12.3.4.9. Analysis of Biosimilar-relatedDeals by Year and Type of Partnership Model
12.3.4.10. Analysis of OtherBiologic-related Deals by Type of Partnership Model
12.3.4.11. Analysis by Type of Biologicsand Geography
12.3.5. Analysisby Therapeutic Area
12.3.6. Analysisof Most Active Players by Number of Partnerships
12.3.7. RegionalAnalysis
12.3.7.1. Intercontinental andIntracontinental Agreements
12.4. Mergersand Acquisitions
12.4.1. AcquisitionsModels
12.4.2. BiopharmaceuticalContract Manufacturing: Mergers and Acquisitions
12.4.3. CumulativeYear-wise Trend
12.4.4. Analysis by Type of Acquisition
12.4.5. GeographicalActivity
12.4.5.1. Mergers and Acquisitions:Continent-wise Distribution
12.4.5.2. Mergers and Acquisitions:Country-wise Distribution
12.4.5.3. Mergers and Acquisitions:Intercontinental and Intracontinental Deals
12.4.6. MostActive Acquirers: Analysis by Number of Acquisitions
12.4.7 Mergersand Acquisitions: Distribution by Key Value Drivers and Type of Biologics
12.4.7.1. Mergers and Acquisitions:Analysis by Key Value Drivers
12.4.7.2. Mergers and Acquisitions:Analysis by Key Value Drivers and Year of Acquisition
12.4.7.3. Mergers and Acquisitions:Analysis by Type of Biologics
12.4.7.4. Mergers and Acquisitions:Analysis by Type of Biologics and Key Value Drivers
12.5. KeyAcquisitions: Deal Multiples
13. RECENTDEVELOPMENTS
13.1. ChapterOverview
13.2. BiopharmaContract Manufacturing Market: Facility Expansions
13.2.1. CumulativeYear-wise Distribution
13.2.2. Analysisby Purpose of Facility Expansion
13.2.3. Analysisby Type of Biologics
13.2.4. Analysisby Type of Biologics and Purpose of Expansion
13.2.5. Analysisby Location of Manufacturing Facility
13.2.6. RegionalAnalysis
13.2.7. MostActive Players: Analysis by Number of Recent Expansions
13.2.8. Analysisby Headquarters and Purpose
13.2.9. FacilityExpansions: Pre-2015 and Post-2015
13.3. BiopharmaceuticalContract Manufacturing Market: Funding Instances
13.4. TechnologicalAdvancements
13.4.1. SingleUse Technology
13.4.2. ProcessAnalytical Technology (PAT)
13.4.3. ContinuousProcessing
13.4.3. Qualityby Design in Bioprocessing
13.3. BiopharmaceuticalContract Manufacturing Market: Funding Instances
13.4. TechnologicalAdvancements
13.4.1. SingleUse Technology
13.4.2. ProcessAnalytical Technology
13.4.3. ContinuousProcessing
13.4.4. Qualityby Design in Bioprocessing
14. CAPACITYANALYSIS
14.1. ChapterOverview
14.2. Assumptionsand Methodology
14.3. BiopharmaceuticalContract Manufacturers: Global Production Capacity
14.3.1. Analysisby Size of the CMO
14.3.2. Analysisby Expression Systems
14.3.3. Analysisby Scale of Operation
14.3.4. Analysisby Region
14.3.4.1. Capacity Analysis: NorthAmerica
14.3.4.2. Capacity Analysis: Europe
14.3.4.3. Capacity Analysis: Asia andMiddle East
14.4. EmergingBiologics: Capacity Analysis
14.4.1. ADCManufacturing Installed Global Capacity: Regional Distribution
14.5. CellTherapy Manufacturing Capacity: Regional Distribution
14.6. ViralVectors Installed Manufacturer Capacity: Distribution by Location ofManufacturing Facility
14.7. ConcludingRemarks
15. DEMANDANALYSIS
15.1. ChapterOverview
15.2. KeyAssumptions and Methodology
15.3. OverallAnnual Demand for Biopharmaceutical Market, 2019-2024
15.3.1. Analysisby Therapeutic Area
15.4. Relationship Between Annual Demand and Capacity
15.5. Demandfor Emerging Novel Biologics
15.5.1. ADCs:Overall Annual Demand
15.5.1. ADCs:Demand and Supply Analysis
16. MARKETFORECAST
16.1. ChapterOverview
16.2. ForecastMethodology and Key Assumptions
16.3. OverallBiopharmaceutical Contract Manufacturing Market, 2019-2030
16.3.1. BiopharmaceuticalContract Manufacturing Market for API Manufacturing, 2019-2030
16.3.2. BiopharmaceuticalContract Manufacturing Market for FDF Manufacturing, 2019-2030
16.4. BiopharmaceuticalContract Manufacturing Market, 2019-2030: Distribution by Expression SystemsUsed
16.5. BiopharmaceuticalContract Manufacturing Market, 2019-2030: Distribution by Scale of Operation
16.6. BiopharmaceuticalContract Manufacturing Market, 2019-2030: Distribution by Size of Manufacturers
16.7. BiopharmaceuticalContract Manufacturing Market, 2019-2030: Distribution by Geography
16.7.1. BiopharmaceuticalContract Manufacturing Market in North America, 2019-2030
16.7.1.1. Biopharmaceutical ContractManufacturing Market in the US, 2019-2030
16.7.1.2. Biopharmaceutical ContractManufacturing Market in Canada, 2019-2030
16.7.1.3. Biopharmaceutical ContractManufacturing Market in North America, 2019-2030: Share of Mammalian Cell-basedOperations
16.7.1.4. Biopharmaceutical ContractManufacturing Market in North America, 2019-2030: Share of Microbial Cell-basedOperations
16.7.1.5. Biopharmaceutical ContractManufacturing Market in North America, 2019-2030: Share of Other ExpressionSystem-based Operations
16.7.1.6. Biopharmaceutical ContractManufacturing Market in North America, 2019-2030: Share of Preclinical /Clinical Scale Operations
16.7.1.7. Biopharmaceutical ContractManufacturing Market in North America, 2019-2030: Share of Commercial ScaleOperations
16.7.1.8. Biopharmaceutical ContractManufacturing Market in North America, 2019-2030: Share of Small-sizedCompanies
16.7.1.9. Biopharmaceutical ContractManufacturing Market in North America, 2019-2030: Share of Mid-sized Companies
16.7.1.10. Biopharmaceutical ContractManufacturing Market in North America, 2019-2030: Share of Large / Very LargeCompanies
16.7.2. BiopharmaceuticalContract Manufacturing Market in Europe, 2019-2030
16.7.2.1. Biopharmaceutical ContractManufacturing Market in Italy, 2019-2030
16.7.2.2. Biopharmaceutical ContractManufacturing Market in Germany, 2019-2030
16.7.2.3. Biopharmaceutical ContractManufacturing Market in France, 2019-2030
16.7.2.4. Biopharmaceutical ContractManufacturing Market in Spain, 2019-2030
16.7.2.5. Biopharmaceutical ContractManufacturing Market in the UK, 2019-2030
16.7.2.6. Biopharmaceutical ContractManufacturing Market in Rest of Europe, 2019-2030
16.7.2.7. Biopharmaceutical ContractManufacturing Market in Europe, 2019-2030: Share of Mammalian Cell-basedOperations
16.7.2.8. Biopharmaceutical ContractManufacturing Market in Europe, 2019-2030: Share of Microbial Cell-basedOperations
16.7.2.9. Biopharmaceutical ContractManufacturing Market in Europe, 2019-2030: Share of Other ExpressionSystem-based Operations
16.7.2.10. Biopharmaceutical ContractManufacturing Market in Europe, 2019-2030: Share of Preclinical / ClinicalOperations
16.7.2.11. Biopharmaceutical ContractManufacturing Market in Europe, 2019-2030: Share of Commercial Operations
16.7.2.12. Biopharmaceutical ContractManufacturing Market in Europe, 2019-2030: Share of Small-sized Companies
16.7.2.13. Biopharmaceutical ContractManufacturing Market in Europe, 2019-2030: Share of Mid-sized Companies
16.7.2.14. Biopharmaceutical ContractManufacturing Market in Europe, 2019-2030: Share of Large / Very LargeCompanies
16.7.3. BiopharmaceuticalContract Manufacturing Market in Asia and Rest of the World, 2019-2030
16.7.3.1. Biopharmaceutical ContractManufacturing Market in China, 2019-2030
16.7.3.2. Biopharmaceutical ContractManufacturing Market in India, 2019-2030
16.7.3.3. Biopharmaceutical ContractManufacturing Market in South Korea, 2019-2030
16.7.3.4. Biopharmaceutical ContractManufacturing Market in Japan, 2019-2030
16.7.3.5. Biopharmaceutical ContractManufacturing Market in Australia, 2019-2030
16.7.3.6. Biopharmaceutical ContractManufacturing Market in Rest of Asia and Other Regions, 2019-2030
16.7.3.7. Biopharmaceutical ContractManufacturing Market in Asia and Rest of the World, 2019-2030: Share ofMammalian Cell-based Operations
16.7.3.8. Biopharmaceutical ContractManufacturing Market in Asia and Rest of the World, 2019-2030: Share ofMicrobial Cell-based Operations
16.7.3.9. Biopharmaceutical ContractManufacturing Market in Asia and Rest of the World, 2019-2030: Share of OtherExpression System-based Operations
16.7.3.10. Biopharmaceutical ContractManufacturing Market in Asia and Rest of the World, 2019-2030: Share ofPreclinical / Clinical Operations
16.7.3.11. Biopharmaceutical ContractManufacturing Market in Asia and Rest of the World, 2019-2030: Share ofCommercial Scale Operations
16.7.3.12. Biopharmaceutical ContractManufacturing Market in Asia and Rest of the World, 2019-2030: Share ofSmall-sized Companies
16.7.3.13. Biopharmaceutical ContractManufacturing Market in Asia and Rest of the World, 2019-2030: Share ofMid-sized Companies
16.7.3.14. Biopharmaceutical ContractManufacturing Market in Asia and Rest of the World, 2019-2030: Large / VeryLarge Companies
16.7.4 OverallBiopharmaceutical Contract Manufacturing, 2019-2030: Share by Others Segment
17. SWOTANALYSIS
17.1 ChapterOverview
17.2. Strengths
17.3. Weaknesses
17.4. Opportunities
17.5. Threats
17.6. Comparisonof Swot Factors
17.7. ConcludingRemarks
18. FUTURE OFTHE BIOPHARMACEUTICAL CMO MARKET
18.1. ChapterOverview
18.2. OutsourcingActivities to Witness Significant Growth in the Coming Years
18.3. Shiftfrom One-time Contracts to Strategic Partnerships
18.4. Integration/ Adoption of New and Innovative Technologies
18.4.1. Singleuse Bioreactors
18.4.2. NovelBioprocess Techniques
18.4.3. BioprocessAutomation
18.5. Focuson Niche Therapeutic Areas
18.6. GrowingBiosimilars Market to Contribute to the Growth of the Contract Services Segment
18.7. Capabilityand Expertise Expansions by CMOs to become One Stop Shops
18.8. OffshoringOutsourcing Activities to Maximize Profits and Expand Existing Capacities
18.9. Increasein Financial Inflow and Outsourcing Budgets
18.10. TheNeed for Humanized Products to Drive the Growth of Mammalian ExpressionTechnologies
18.11. ChallengesFaced by both Sponsors and Service Providers
18.11.1. Concerns related to Single UseSystems
18.11.2. Issues Related to CapacityFluctuations
18.12. ConcludingRemarks
19. SURVEYANALYSIS
19.1. ChapterOverview
19.1.1. Overviewof Respondents
19.1.2. Designationof Respondents
19.2. BiologicsManufacturing Expertise
19.3. Scaleof Manufacturing
19.4. Locationof Production Facilities
19.5. Typesof Expression Systems Used
19.6. Typesof Bioreactors
19.7. Modesof Operation of Bioreactors
20. INTERVIEWTRANSCRIPTS
20.1. ChapterOverview
20.2. AstridBrammer, Senior Manager Business Development, Richter-Helm
20.3. BirgitSchwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
20.4. ChristianBailly, Director of CDMO, Pierre Fabre
20.5. ClaireOtjes, Assistant Marketing Manager, Batavia Biosciences
20.6. DavidC Cunningham, Director Corporate Development, Goodwin Biotechnology
20.7. DietmarKatinger, Chief Executive Officer, Polymun Scientific
20.8. DenisAngioletti, Chief Commercial Officer, Cerbios-Pharma
20.9. JeffreyHung, Chief Commercial Officer, Vigene Biosciences
20.10. KevinDaley, Director Pharmaceuticals, Novasep
20.11. MarkWright, Site Head, Grangemouth, Piramal Healthcare
20.12. NicolasGrandchamp, R&D Leader, GEG Tech
20.13. RaquelFortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
20.14. SebastianSchuck, Head of Business Development, Wacker Biotech
20.15. StephenTaylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
20.16. TatjanaBuchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager,Plasmid Factory
20.17. Tim Oldham, Chief Executive Officer, Cell Therapies
21. APPENDIX 1: LISTOF NON-INDUSTRY PLAYERS
22. APPENDIX 2:TABULATED DATA
23. APPENDIX 3: LISTOF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
